GlassScriptPhysician profile
John G Larsen
NPI 1700974169
$2,827.06
in general payments reported to CMS, 2019-2025
33 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Pediatric Infectious Diseases provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $170 · 2021: $379 · 2022: $324 · 2023: $676 · 2024: $276 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $825.56 | 2019-2025 | Bexsero, Pediarix |
| Kaleo, INC. | $426.20 | 2019-2024 | Auvi-Q |
| Tepha INC | $399.31 | 2019 | |
| Genentech USA, INC. | $93.54 | 2019-2024 | Xolair |
| Novo Nordisk INC | $79.28 | 2019-2024 | Sogroya |
| Sanofi Pasteur INC. | $76.36 | 2023 | |
| Merck Sharp & Dohme LLC | $71.52 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Azurity Pharmaceuticals, INC. | $65.19 | 2023-2025 | Triptodur, Triptodur |
| Hologic Sales and Service, LLC | $60.18 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Ascendis Pharma Endocrinology INC | $54.88 | 2022-2023 | |
| Seqirus USA INC | $52.01 | 2022-2023 | Flucelvax Quadrivalent |
| Amneal Pharmaceuticals LLC | $49.94 | 2022-2023 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $48.63 | 2021-2023 | Flumist Quadrivalent |
| Pfizer INC. | $47.11 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $45.16 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $43.01 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $38.43 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $34.46 | 2021 | |
| Genzyme Corporation | $31.49 | 2023 | |
| Cranial Technologies, INC | $30.48 | 2023-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $26.66 | 2024 | Cuvitru |
| Abbvie INC. | $26.11 | 2022 | |
| Tolmar, INC. | $23.38 | 2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $22.98 | 2025 | |
| Aimmune Therapeutics, INC. | $21.06 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.62 | 2021 | |
| Alk-Abello, INC | $20.16 | 2025 | Neffy |
| Phadia US INC. | $19.87 | 2025 | Immunocap |
| Verrica Pharmaceuticals INC. | $17.62 | 2024 | Ycanth |
| Polynovo North America LLC | $15.93 | 2025 | Novosorb Btm |
| Avion Pharmaceuticals | $15.77 | 2019 | |
| Endo Pharmaceuticals INC. | $12.22 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.